Quick Answer
Kairos Pharma, LTD. reported R&D Expense of $2.13 million for fiscal year 2025.
Kairos Pharma, LTD. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $2.13M | +415.7% |
| 2024 | $414.0K | +404.9% |
| 2023 | $82.0K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $608.0K | +4242.9% | +22.6% |
| June 30, 2025 | $496.0K | +687.3% | +0.6% |
| March 31, 2025 | $493.0K | +198.8% | +3421.4% |
| September 30, 2024 | $14.0K | -57.6% | -77.8% |
| June 30, 2024 | $63.0K | — | -61.8% |
| March 31, 2024 | $165.0K | — | +400.0% |
| September 30, 2023 | $33.0K | — | — |
- Kairos Pharma, LTD. showed an increase of +415.7% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, Kairos Pharma, LTD.’s r&d expense has grown by 2503.7% (from $82.0 thousand to $2.13 million).
- The most recent figure is from Kairos Pharma, LTD.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: